10-Q: Solsence Reports Q3 2026 Growth Amidst Financial Restatement

Solsence, Inc. announced a significant increase in quarterly revenue and a return to profitability for Q3 2026, following a financial restatement impacting prior periods.

Summary

• Solsence, Inc. reported total revenue of $20.16 million for the third quarter of 2026, a substantial increase from $14.60 million in the same period of 2025.
• For the nine months ended September 30, 2026, total revenue was $48.45 million, a slight decrease from $49.58 million in the prior year.
• Net income for the third quarter of 2026 was $3.67 million, a significant improvement from a net loss of $1.02 million in Q3 2025.
• Net income for the nine months ended September 30, 2026, was $2.48 million, down from $2.54 million in the comparable period of 2025.
• The company identified and restated errors in historical accounting for labor and manufacturing overhead included in inventories, leading to a reduction in inventories by $3.63 million as of December 31, 2025.
• The company experienced a material weakness in internal control over financial reporting related to inventory costing and oversight of financial reporting, which is being addressed through remediation activities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth in the quarter and improved net income, despite ongoing challenges and a restatement impacting prior periods.

Positives

• Total revenue for Q3 2026 increased by 38.1% to $20.16 million compared to $14.60 million in Q3 2025, driven by stronger demand from brand partners.
• Net income for Q3 2026 was $3.67 million, a significant turnaround from a net loss of $1.02 million in Q3 2025.
• Gross profit for Q3 2026 more than doubled to $7.93 million from $3.47 million in Q3 2025.
• Net cash provided by operating activities for the nine months ended September 30, 2026, was $8.43 million, a strong recovery from a use of $10.39 million in the same period of 2025.
• The company's technology suite, including Active Stress Defense, Blm, Chromalm, and WHSPR, continues to be a core focus for innovation and competitive advantage.

Negatives

• Total revenue for the nine months ended September 30, 2026, decreased by 2.3% to $48.45 million compared to $49.58 million in the same period of 2025.
• The company reported a material weakness in internal control over financial reporting related to inventory costing and oversight of financial reporting.
• A restatement of previously issued financial statements was necessary due to errors in historical accounting for labor and manufacturing overhead included in inventories.
• The company's reliance on three significant customers, accounting for 68% of Q3 2026 revenue and 65% of year-to-date revenue, presents a concentration risk.
• The company anticipates that supplier price increases and wage and benefit inflation may materially affect its operations and financial position in 2026 and beyond.

Risks

• The company's dependence on a limited number of key customers could lead to significant revenue fluctuations if a customer cancels a purchase order or supply agreement.
• The terms of supply agreements with BASF could trigger a requirement to sell production equipment, potentially impacting revenue.
• The company may face challenges in obtaining working capital on acceptable terms or at all.
• Uncertain demand for and acceptance of its Solsence products and advanced materials could impact future growth.
• Potential inability to pass through cost increases to customers due to contractual limitations or market conditions could reduce margins and net income.
• The company is subject to potential limitations on the utilization of its federal net operating loss carryforwards due to future ownership changes.
• The company faces risks related to the resolution of litigation or other legal proceedings.
• Potential new governmental regulations, especially concerning nanomaterials, could be difficult or costly to comply with.

Future Outlook

The company expects supplier price increases and wage and benefit inflation to potentially impact operations and financial position in 2026 and beyond, and will attempt to pass these costs to customers. Capital spending for 2026 is projected between $0.5 million and $1.5 million, funded by operations, existing loans, and potential new debt financing.

Management Comments

• Management believes inflation has not had a material effect on operations or financial position for 2026, but anticipates future impacts.
• Management is focused on improving overall equipment effectiveness and throughput through lean management to maintain a competitive cost position and drive operating margin improvements.
• Management believes its patented technologies create a competitive advantage for customers, enabling differentiation and market share gains.

Industry Context

StockSavvy.ai notes that Solsence operates in the competitive consumer health and beauty markets, focusing on advanced materials and skin health products. The company's strategy relies on proprietary technologies and vertical integration. The reported revenue growth in the quarter, despite a slight year-to-date decline, suggests a positive short-term demand trend for its consumer products, while the personal care ingredients segment shows mixed performance.

Legal Proceedings

• A Settlement Agreement and Release was entered into with Refy Beauty Ltd on July 6, 2026, to resolve disputes relating to certain consumer care products. A settlement expense and liability of $938,000 was recognized in June 2026.

Related Party Transactions

• The company has outstanding balances with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore.
• Outstanding balances with Beachcorp, LLC were $7,330,000 as of September 30, 2026, down from $14,267,000 as of December 31, 2025.
• Outstanding balances with Strandler, LLC were $1,000,000 as of September 30, 2026, and December 31, 2025.
• Related party interest expense was $798,000 for the nine months ended September 30, 2026, and $795,000 for the same period in 2025.

Stakeholder Impact

• Shareholders may be impacted by the ongoing efforts to remediate material weaknesses in internal controls and the restatement of prior financial periods.
• Customers may benefit from stronger demand and improved product offerings, as indicated by the quarterly revenue growth.
• Suppliers may face potential price increases and inflation, which the company aims to pass on.
• Creditors, particularly related parties like Beachcorp, LLC and Strandler, LLC, are impacted by the company's debt levels and repayment activities.

Next Steps

• Implement remediation measures for material weaknesses in internal control over financial reporting.
• Continue to expand reach within foreign markets as part of the 'Transform and Transcend' strategic initiative.
• Focus on improving overall equipment effectiveness and throughput through lean management.
• Continue innovation efforts in new IP for environmental protection and complementary technologies.
• The company's 2026 Annual Meeting of Stockholders is scheduled for December 16, 2026.

Key Dates

Recommendation

The company shows signs of recovery with strong quarterly revenue growth and a return to profitability. However, the material weaknesses in internal controls, the need for financial restatements, and customer concentration risks warrant a cautious approach. Further progress in remediating control issues and sustained revenue growth across all segments would be needed to consider a more positive outlook.

Keywords

Consumer Health, Skin Health, Personal Care Ingredients, Advanced Materials, SPF Protection, Inventory Restatement, Material Weakness, Revenue Growth